Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”

Draft guidance from FDA would adopt the International Conference on Harmonization’s periodic benefit-risk evaluation reports, which will offer sponsors the opportunity to provide updates on benefit information along with safety signals to the regulatory authorities.